Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

K. E. Caudle, C. F. Thorn, T. E. Klein, J. J. Swen, H. L. McLeod, R. B. Diasio, M. Schwab

Research output: Contribution to journalReview article

221 Scopus citations

Abstract

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)640-645
Number of pages6
JournalClinical pharmacology and therapeutics
Volume94
Issue number6
DOIs
StatePublished - Dec 2013

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing'. Together they form a unique fingerprint.

  • Cite this